FDA Ad Letters Focus On Superiority Claims; Oversight Critiqued On Several Fronts
Executive Summary
FDA appears to have shifted the focus of its advertising oversight and is concentrating on superiority claims as opposed to safety issues; the agency also seems to have relaxed the tone of its enforcement, relying more on "untitled" letters than it has in the past
You may also be interested in...
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
FDA's Advertising Letters Continue To Grow, Both In Volume And Depth
FDA's Division of Drug Marketing, Advertising and Communication appears to be shifting the way it writes citations to firms, increasing not just the number of letters it sends, but the number of problems it lists within each letter
Advertising Citations Reach Record High: Another Way To Regulate Pharma?
FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month